Polpharma looks to invest and not a new owner

At the same time, he rejects speculation about a possible sale of the company and stresses that Polpharma will continue investing in production. Polpharma prepared investments totalling zł.120 million in 2005, which include the completion of current projects underway like the modernization of its capsules production line. Until now, the company invested zł.527 million in fixed assets and its two latest projects are the creation of a R&D center at a cost of zł.32 million and injection medicines department at zł.49 million. Polpharma also intends to develop its very profitable chemical department as well as strive for cooperation with Novartis in order to produce and sell one of the group's patented medicines. In 2004 Polpharma had sales of zł. 868 million. (Puls Biznesu pp.1, 13) M.G.